Cardiovascular diseases (CVDs) stand as the leading cause of death worldwide, posing a significant global health challenge. Consequently, the development of innovative therapeutic strategies to enhance CVDs treatment is imperative. RNA-based therapies, encompassing non-coding RNAs, mRNA, aptamers, and CRISPR/Cas9 technology, have emerged as promising tools for addressing CVDs. However, inherent challenges associated with RNA, such as poor cellular uptake, susceptibility to RNase degradation, and capture by the reticuloendothelial system, underscore the necessity of combining these therapies with effective drug delivery systems.

中文翻译：

---

探索心血管疾病治疗中 RNA 递送系统的前景

心血管疾病（CVD）是全球主要死亡原因，构成了重大的全球健康挑战。因此，开发创新的治疗策略来加强心血管疾病的治疗势在必行。基于 RNA 的疗法，包括非编码 RNA、mRNA、适体和 CRISPR/Cas9 技术，已成为治疗 CVD 的有前景的工具。然而，与 RNA 相关的固有挑战，例如细胞摄取不良、对 RNase 降解敏感以及被网状内皮系统捕获，强调了将这些疗法与有效的药物递送系统相结合的必要性。